LONDON--(BUSINESS WIRE)--Lightlake Therapeutics Inc. (OTCBB: LLTP) (the “Company” or “Lightlake”), an early stage biopharmaceutical company using its expertise of opioid antagonists to develop modern addiction treatments, announced today that it will conduct Phase II trials at King’s College London on an opioid antagonist-based nasal spray treatment for Bulimia Nervosa.
